The importance of treatment sequencing with <scp>SGLT2</scp> inhibitors and <scp>GLP</scp> ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes

In people with T2D receiving combination therapy, initiating treatment with a SGLT2i was associated with greater long-term preservation of kidney function compared with starting with a GLP-1RA. Early SGLT2i use may confer better renal protection even when GLP-1RA intensification is subsequently required, confirming SGLT2i as a foundational therapy for preventing the decline in renal function in T2D.